Exploring Latest Expansions in Solid Lipid-based Nanoparticle Technology for Treatment of Cancer

Area of Science:

• Nanotechnology
• Biomedical Engineering
• Pharmaceutical Sciences

Background:

• Conventional chemotherapy faces limitations including poor bioavailability, drug degradation, and non-specific targeting.
• Solid lipid nanoparticles (SLNs) utilize biocompatible lipids as carriers, offering improved drug encapsulation and stability.
• SLNs address key challenges in cancer therapy by providing controlled release and enhanced drug protection.

Purpose of the Study:

• To provide a comprehensive overview of current advancements in solid lipid-based nanoparticle (SLN) technology for cancer treatment.
• To highlight the potential of SLNs in overcoming the limitations of traditional chemotherapy.
• To explore the role of SLNs in personalized and precision cancer therapies.

Main Methods:

• Optimization of SLN formulation parameters for drug loading, stability, and release kinetics.
• Application of advanced fabrication techniques such as high-pressure homogenization and microemulsion methods.
• Surface modification of SLNs with ligands or antibodies for active targeting of tumor cells.

Main Results:

• SLNs demonstrate enhanced drug encapsulation, protection from degradation, and controlled release profiles.
• Passive accumulation of SLNs in tumor tissues via enhanced penetration and retention (EPR) effects.
• Surface modifications enable active targeting, improving selectivity and reducing side effects on healthy tissues.

Conclusions:

• SLN technology represents a significant advancement in cancer therapy, offering improved efficacy and reduced toxicity.
• Preclinical and clinical studies show promising therapeutic outcomes with SLN-based anticancer formulations.
• The versatility of SLNs positions them as a key technology for the future of personalized and precision cancer treatment.